1Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.
2Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea.
3Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.
4Department of Internal Medicine, Soonchunhyang University College of Medicine, Cheonan, Korea.
5Department of Internal Medicine, Sun General Hospital, Daejeon, Korea.
Copyright © 2011 Korean Diabetes Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Data are presented by mean±standard deviation.
CO, control Otsuka-Long-Evans-Tokushima-Fatty (OLETF) group; SPR, spironolactone-treated OLETF group; LO, losartan-treated OLETF group; COM, spironolactone- and losartan-treated OLETF group; ACR, albumin-creatinine ratio.
aP value vs. CO group, bP<0.05 compared with CO group.
Data are presented by mean±standard deviation. CO, control Otsuka-Long-Evans-Tokushima-Fatty (OLETF) group; SPR, spironolactone-treated OLETF group; LO, losartan-treated OLETF group; COM, spironolactone- and losartan-treated OLETF group; ACR, albumin-creatinine ratio. a